Twenty years ago, Stryker saw the potential that biologics held for orthopedics. Although the biotechnology industry was then in its infancy and its products unproven, Stryker invested in a proprietary, recombinant version of bone morphogenetic protein-7 (rhBMP-7) also known as OP-1, and persevered through years of development, clinical trials and regulatory filings. In 2001 our vision was validated with marketing authorization for OP-1 by Australia, Canada, the European Union and the United States for specific indications involving long-bone fractures. Stryker is also investigating spinal applications for OP-1 through clinical trials in North America and Japan. Stryker Biotech is located in Hopkinton, Massachusetts and has manufacturing facilities in New Hampshire and Ireland.